Dr. Marshall Posner, has 40 years of experience in clinical oncology and in clinical and translational research. He is currently an Associate Director for Cancer Clinical Research Tampa General Hospital/Cancer Center of South Florida. Prior to that, he served as a Professor of Medicine, Director of Head and Neck Medical Oncology, Associate Director of the Centre for Personalized Cancer Therapeutics, and Co-Leader of the Cancer Clinical Investigation Program for The Tisch Cancer Institute- Icahn School of Medicine at Mount Sinai. Dr. Posner specializes in multimodality treatments for advanced-stage head and neck squamous cell carcinoma (HNSCC). He is a pioneer in the field of immunotherapy and precision oncology. Dr. Posner played a leading role in the creation of the TPF (docetaxel, cisplatin, and 5-fluorouracil) regimen for neoadjuvant therapy in HNSCC, which has become the international standard of care. As the Principal Investigator of the landmark TAX 324 trial, he devised and led this major study, revolutionizing treatment strategies for HNSCC by establishing sequential therapy as a means to improve outcomes while reducing toxicity.